Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disease characterized by neurological symptoms and signs of progressive weakness, paresthesias, and sensory dysfunction. Other symptoms include reduced or absent tendon reflexes, cranial nerve involvement, autonomic symptoms,...
Autores Principales: | , , , , , , |
---|---|
Formato: | Artículo (Article) |
Lenguaje: | Inglés (English) |
Publicado: |
Academic Press
2019
|
Materias: | |
Acceso en línea: | https://repository.urosario.edu.co/handle/10336/22243 https://doi.org/10.1016/j.jaut.2019.04.021 |
id |
ir-10336-22243 |
---|---|
recordtype |
dspace |
spelling |
ir-10336-222432022-05-02T12:37:16Z Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease Rodríguez Y. Vatti N. Ramirez-Santana, Carolina Chang C. Mancera-Páez O. Gershwin M.E. Anaya, Juan-Manuel Connexin 32 Contactin 1 Contactin associated protein 1 Corticosteroid derivative Cyclophosphamide Immunoglobulin Methotrexate Mycophenolate mofetil Myelin basic protein Myelin protein Neurofascin 155 Peripheral myelin protein 22 Rituximab Unclassified drug Adaptive immunity Ataxia Bartonella henselae Chronic inflammatory demyelinating polyneuropathy Clinical feature Clinical practice Cytomegalovirus Environmental factor Epstein barr virus Hepatitis b virus Hepatitis c virus Heredity Human Human immunodeficiency virus Humoral immunity Immunosuppressive treatment Mycoplasma pneumoniae Nerve conduction Neuropathic pain Paresthesia Pathogenesis Plasma exchange Priority journal Ranvier node Reflex disorder Review Sensory dysfunction Tendon reflex Weakness Autoimmune disease Autoimmune ecology Autoimmune tautology Chronic inflammatory demyelinating polyradiculoneuropathy Guillain-barré syndrome Molecular mimicry Polyautoimmunity Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disease characterized by neurological symptoms and signs of progressive weakness, paresthesias, and sensory dysfunction. Other symptoms include reduced or absent tendon reflexes, cranial nerve involvement, autonomic symptoms, ataxia, and neuropathic pain. Unlike other autoimmune diseases, CIDP generally affects older individuals and has a male predominance. The onset is generally insidious and can take up to 8 weeks with a relapsing-recovery pattern. Like all autoimmune diseases, the etiology is multifactorial, with both genetic and environmental factors contributing to it. Case reports of CIDP have found associations with multiple pathogenic organisms including Hepatitis B and C viruses, Bartonella henselae, Mycoplasma pneumoniae, Human immunodeficiency virus, Cytomegalovirus and Epstein-Barr virus. Possible antigenic self-targets include myelin protein 0, myelin protein 2, peripheral myelin protein 22, Connexin 32, and myelin basic protein. Antibodies targeting the Ranvier node proteins such as contactin-1, contactin-associated protein 1, and neurofascin 155 have been described. CIDP is treated with rehabilitation and pharmacological modalities. Pharmacological treatments target autoimmune dysfunction and include corticosteroids, intravenous immunoglobulin, subcutaneous immunoglobulin, plasma exchange, immunosuppressive and immunomodulatory agents such as methotrexate, cyclophosphamide, rituximab, and mycophenolate mofetil. Although there are few observational studies and randomized clinical trials with limited evidence supporting the use of immunosuppressive drugs, they are widely used in clinical practice. A comprehensive review of CIDP is presented herein in light of the autoimmune tautology. © 2019 Elsevier Ltd 2019 2020-05-25T23:55:51Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion 10959157 08968411 https://repository.urosario.edu.co/handle/10336/22243 https://doi.org/10.1016/j.jaut.2019.04.021 eng info:eu-repo/semantics/openAccess application/pdf Academic Press instname:Universidad del Rosario |
institution |
EdocUR - Universidad del Rosario |
collection |
DSpace |
language |
Inglés (English) |
topic |
Connexin 32 Contactin 1 Contactin associated protein 1 Corticosteroid derivative Cyclophosphamide Immunoglobulin Methotrexate Mycophenolate mofetil Myelin basic protein Myelin protein Neurofascin 155 Peripheral myelin protein 22 Rituximab Unclassified drug Adaptive immunity Ataxia Bartonella henselae Chronic inflammatory demyelinating polyneuropathy Clinical feature Clinical practice Cytomegalovirus Environmental factor Epstein barr virus Hepatitis b virus Hepatitis c virus Heredity Human Human immunodeficiency virus Humoral immunity Immunosuppressive treatment Mycoplasma pneumoniae Nerve conduction Neuropathic pain Paresthesia Pathogenesis Plasma exchange Priority journal Ranvier node Reflex disorder Review Sensory dysfunction Tendon reflex Weakness Autoimmune disease Autoimmune ecology Autoimmune tautology Chronic inflammatory demyelinating polyradiculoneuropathy Guillain-barré syndrome Molecular mimicry Polyautoimmunity |
spellingShingle |
Connexin 32 Contactin 1 Contactin associated protein 1 Corticosteroid derivative Cyclophosphamide Immunoglobulin Methotrexate Mycophenolate mofetil Myelin basic protein Myelin protein Neurofascin 155 Peripheral myelin protein 22 Rituximab Unclassified drug Adaptive immunity Ataxia Bartonella henselae Chronic inflammatory demyelinating polyneuropathy Clinical feature Clinical practice Cytomegalovirus Environmental factor Epstein barr virus Hepatitis b virus Hepatitis c virus Heredity Human Human immunodeficiency virus Humoral immunity Immunosuppressive treatment Mycoplasma pneumoniae Nerve conduction Neuropathic pain Paresthesia Pathogenesis Plasma exchange Priority journal Ranvier node Reflex disorder Review Sensory dysfunction Tendon reflex Weakness Autoimmune disease Autoimmune ecology Autoimmune tautology Chronic inflammatory demyelinating polyradiculoneuropathy Guillain-barré syndrome Molecular mimicry Polyautoimmunity Rodríguez Y. Vatti N. Ramirez-Santana, Carolina Chang C. Mancera-Páez O. Gershwin M.E. Anaya, Juan-Manuel Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease |
description |
Chronic inflammatory demyelinating polyneuropathy (CIDP) is an autoimmune disease characterized by neurological symptoms and signs of progressive weakness, paresthesias, and sensory dysfunction. Other symptoms include reduced or absent tendon reflexes, cranial nerve involvement, autonomic symptoms, ataxia, and neuropathic pain. Unlike other autoimmune diseases, CIDP generally affects older individuals and has a male predominance. The onset is generally insidious and can take up to 8 weeks with a relapsing-recovery pattern. Like all autoimmune diseases, the etiology is multifactorial, with both genetic and environmental factors contributing to it. Case reports of CIDP have found associations with multiple pathogenic organisms including Hepatitis B and C viruses, Bartonella henselae, Mycoplasma pneumoniae, Human immunodeficiency virus, Cytomegalovirus and Epstein-Barr virus. Possible antigenic self-targets include myelin protein 0, myelin protein 2, peripheral myelin protein 22, Connexin 32, and myelin basic protein. Antibodies targeting the Ranvier node proteins such as contactin-1, contactin-associated protein 1, and neurofascin 155 have been described. CIDP is treated with rehabilitation and pharmacological modalities. Pharmacological treatments target autoimmune dysfunction and include corticosteroids, intravenous immunoglobulin, subcutaneous immunoglobulin, plasma exchange, immunosuppressive and immunomodulatory agents such as methotrexate, cyclophosphamide, rituximab, and mycophenolate mofetil. Although there are few observational studies and randomized clinical trials with limited evidence supporting the use of immunosuppressive drugs, they are widely used in clinical practice. A comprehensive review of CIDP is presented herein in light of the autoimmune tautology. © 2019 Elsevier Ltd |
format |
Artículo (Article) |
author |
Rodríguez Y. Vatti N. Ramirez-Santana, Carolina Chang C. Mancera-Páez O. Gershwin M.E. Anaya, Juan-Manuel |
author_facet |
Rodríguez Y. Vatti N. Ramirez-Santana, Carolina Chang C. Mancera-Páez O. Gershwin M.E. Anaya, Juan-Manuel |
author_sort |
Rodríguez Y. |
title |
Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease |
title_short |
Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease |
title_full |
Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease |
title_fullStr |
Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease |
title_full_unstemmed |
Chronic inflammatory demyelinating polyneuropathy as an autoimmune disease |
title_sort |
chronic inflammatory demyelinating polyneuropathy as an autoimmune disease |
publisher |
Academic Press |
publishDate |
2019 |
url |
https://repository.urosario.edu.co/handle/10336/22243 https://doi.org/10.1016/j.jaut.2019.04.021 |
_version_ |
1740172491068801024 |
score |
12,131701 |